MARKET

DFFN

DFFN

Diffusion Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8190
-0.0084
-1.02%
Opening 10:01 09/22 EDT
OPEN
0.8050
PREV CLOSE
0.8274
HIGH
0.8198
LOW
0.8050
VOLUME
98.93K
TURNOVER
--
52 WEEK HIGH
2.200
52 WEEK LOW
0.2110
MARKET CAP
52.41M
P/E (TTM)
-0.8008
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DFFN: First Patients Dosed in COVID-19 Trial…
By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update First Patients Dosed in COVID-19 Trial On September 10, 2020, Diffusion Pharmacueticals, Inc. (NASDAQ:DFFN) announced that the first two patients have been dosed in the open-label Phase 1b clinical trial of trans sodium
Zacks Small Cap Research · 4d ago
We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Simply Wall St. · 09/15 12:12
Diffusion Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference
CHARLOTTESVILLE, Va., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced its management will present at the H.C. Wainwright 22nd Annual Global Investment Conference to be held virtually on September 14-16, 2020. Robert Cobuzzi
GlobeNewswire · 09/11 12:30
Diffusion Pharmaceuticals Doses First Two Patients with TSC in COVID-19 Clinical Trial
Twenty-four patient Phase 1b safety and tolerability study initiated in RomaniaCHARLOTTESVILLE, Va., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”) today announced dosing of the first two patients in the Company’s open-label Phase 1b lead-in
GlobeNewswire · 09/10 13:00
Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer
CHARLOTTESVILLE, Va., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that Robert (“Bob”) J. Cobuzzi Jr., Ph.D., who has served as a member of the Company’s Board of Directors since January 2020, will succeed David G. Kalergis
GlobeNewswire · 09/08 21:02
Diffusion Pharmaceuticals Appoints Jane H. Hollingsworth to its Board of Directors
Romanian Regulatory Approval Received to Begin Phase 1b COVID-19 Clinical TrialCHARLOTTESVILLE, Va., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a biotechnology company developing new treatments for life-threatening medical conditions
GlobeNewswire · 09/01 21:02
DFFN: ARDS Trial Set to Get Underway
By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update ARDS Trial to Initiate Soon On July 27, 2020, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced receipt of guidance from the U.S. FDA on the IND application to test trans sodium crocetinate (TSC) in COVID-19 patients suffering from acute respiratory distress syndrome (ARDS). The guidance suggested certain
Zacks Small Cap Research · 08/24 13:32
From Benzinga's PreMarket Prep: Co-Host Dennis Dick Says If He Was In Plasma Stocks Right Now He Would Sell Them; Notes 'This Is A Gift I Would Ring The Register Right Now'
Benzinga · 08/24 12:32
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DFFN stock price target is 2.750 with a high estimate of 3.500 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 39
Institutional Holdings: 6.07M
% Owned: 9.49%
Shares Outstanding: 64.00M
TypeInstitutionsShares
Increased
6
1.95M
New
23
61.62K
Decreased
1
30.77K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average DFFN stock price target is 2.750 with a high estimate of 3.500 and a low estimate of 2.000.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DFFN
Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Diffusion Pharmaceuticals Inc stock information, including NASDAQ:DFFN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DFFN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DFFN stock methods without spending real money on the virtual paper trading platform.